Stay Hydrated: Drinking plenty of water helps flush out toxins and ensures proper cell function, including glutathione synthesis
But not every GLP-1 user was previously obese
The FDA has approved a higher dose version of the GLP-1 drug Wegovy for weight loss
Responding to recent news that its long-shot potential Alzheimers indication for Wegovy did not Analysts Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives
Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear
If you are wondering what to expect, here is a clear guide
.jpg)
